CG Oncology reports Q1 net loss $16.9M; cash $566.5M; cretostimogene 75.2% CR rate in BCG-unresponsive NMIBC

CG Oncology, Inc.

2024-Q1 EPS reported -$0.36 revenue$529,000

Net loss $16.9M ($0.36/sh) in Q1 2024 vs $12.4M ($3.22/sh) Q1 2023; R&D expense $17.2M (up from $7.8M).
Cash and securities $566.5M as of Mar 31, 2024, compared to $187.7M at Dec 31, 2023; runway sufficient through 2027.
Cretostimogene monotherapy achieved 75.2% complete response (79/105) in BOND-003 Phase 3 trial in BCG-unresponsive HR-NMIBC.
Completed oversubscribed $437M IPO in 2024; first Pt dosed in PIVOT-006 Phase 3; CORE-001 combo data to be presented at ASCO June 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

CG Oncology, Inc. reported the first quarter ended March 31, 2024 results: net income $16.9 million, or ($0.36) per share, EPS ($0.36) per share.

Period: the first quarter ended March 31, 2024
Net income: $16.9 million, or ($0.36) per share
EPS: ($0.36) per share
Result: reported results

Exact text from the filing

CG Oncology, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

CG Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-134805

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.